Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 37 | 2023 | 1383 | 6.510 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 33 | 2025 | 1434 | 3.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 65 | 2024 | 11868 | 2.420 |
Why?
|
Lymphoma, Non-Hodgkin | 25 | 2021 | 1376 | 2.410 |
Why?
|
Lymphoma, Follicular | 10 | 2024 | 459 | 1.770 |
Why?
|
Burkitt Lymphoma | 6 | 2021 | 338 | 1.550 |
Why?
|
Stem Cell Transplantation | 18 | 2023 | 1602 | 1.290 |
Why?
|
Lymphoma, Mantle-Cell | 11 | 2020 | 238 | 1.290 |
Why?
|
Vincristine | 22 | 2024 | 1039 | 1.250 |
Why?
|
Salvage Therapy | 9 | 2020 | 1272 | 1.170 |
Why?
|
Lymphoma, B-Cell | 9 | 2021 | 943 | 1.140 |
Why?
|
Doxorubicin | 28 | 2024 | 2230 | 1.130 |
Why?
|
Transplantation, Autologous | 20 | 2023 | 2120 | 1.100 |
Why?
|
Cyclophosphamide | 28 | 2024 | 2228 | 1.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 19 | 2014 | 691 | 1.000 |
Why?
|
Positron-Emission Tomography | 21 | 2022 | 6547 | 0.920 |
Why?
|
Lymphoma | 11 | 2023 | 1897 | 0.890 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2024 | 1646 | 0.840 |
Why?
|
Herpesvirus 4, Human | 5 | 2021 | 1078 | 0.830 |
Why?
|
Vinblastine | 11 | 2023 | 483 | 0.770 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2021 | 617 | 0.750 |
Why?
|
Prednisone | 16 | 2024 | 1565 | 0.740 |
Why?
|
Dacarbazine | 10 | 2023 | 552 | 0.680 |
Why?
|
Mediastinal Neoplasms | 6 | 2018 | 403 | 0.670 |
Why?
|
Hematopoietic Stem Cell Transplantation | 17 | 2023 | 5753 | 0.650 |
Why?
|
Education, Graduate | 1 | 2019 | 75 | 0.610 |
Why?
|
Lymphoma, T-Cell | 2 | 2014 | 309 | 0.590 |
Why?
|
Disease-Free Survival | 31 | 2023 | 6832 | 0.580 |
Why?
|
Music Therapy | 3 | 2023 | 111 | 0.540 |
Why?
|
Etoposide | 13 | 2020 | 636 | 0.540 |
Why?
|
Lymphoproliferative Disorders | 3 | 2010 | 526 | 0.530 |
Why?
|
Immune Evasion | 1 | 2019 | 377 | 0.510 |
Why?
|
Proto-Oncogene Proteins c-myc | 5 | 2018 | 995 | 0.500 |
Why?
|
Fellowships and Scholarships | 3 | 2022 | 1135 | 0.470 |
Why?
|
Neoplasm Staging | 25 | 2024 | 11206 | 0.470 |
Why?
|
Bleomycin | 8 | 2023 | 491 | 0.460 |
Why?
|
Fluorodeoxyglucose F18 | 9 | 2016 | 2024 | 0.460 |
Why?
|
Immunoconjugates | 3 | 2018 | 981 | 0.450 |
Why?
|
Lymph Nodes | 3 | 2023 | 3454 | 0.440 |
Why?
|
Recurrence | 19 | 2023 | 8501 | 0.440 |
Why?
|
Radiopharmaceuticals | 7 | 2017 | 2699 | 0.430 |
Why?
|
Humans | 162 | 2025 | 765968 | 0.420 |
Why?
|
Transplantation Conditioning | 9 | 2023 | 1635 | 0.420 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2014 | 169 | 0.420 |
Why?
|
Hematology | 3 | 2022 | 243 | 0.420 |
Why?
|
Lymphoma, T-Cell, Peripheral | 3 | 2023 | 125 | 0.410 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 192 | 0.410 |
Why?
|
Career Choice | 1 | 2019 | 769 | 0.410 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2012 | 120 | 0.390 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2014 | 296 | 0.380 |
Why?
|
Antibodies | 1 | 2019 | 2417 | 0.380 |
Why?
|
Prognosis | 26 | 2024 | 29922 | 0.370 |
Why?
|
Immunotherapy, Adoptive | 3 | 2025 | 1510 | 0.360 |
Why?
|
Vidarabine | 2 | 2024 | 343 | 0.350 |
Why?
|
Antineoplastic Agents | 21 | 2023 | 13648 | 0.350 |
Why?
|
Adult | 79 | 2025 | 223044 | 0.340 |
Why?
|
Treatment Outcome | 43 | 2025 | 65188 | 0.330 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 180 | 0.320 |
Why?
|
Combined Modality Therapy | 12 | 2024 | 8529 | 0.310 |
Why?
|
Cytarabine | 8 | 2020 | 698 | 0.300 |
Why?
|
Female | 90 | 2025 | 396112 | 0.300 |
Why?
|
Referral and Consultation | 2 | 2014 | 3615 | 0.300 |
Why?
|
Male | 90 | 2025 | 363698 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2023 | 9373 | 0.300 |
Why?
|
Antibodies, Monoclonal | 8 | 2023 | 9249 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2022 | 1410 | 0.290 |
Why?
|
Disease Management | 4 | 2024 | 2535 | 0.280 |
Why?
|
Middle Aged | 75 | 2025 | 223009 | 0.270 |
Why?
|
Medication Adherence | 1 | 2018 | 2192 | 0.270 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2014 | 1801 | 0.270 |
Why?
|
Heart Neoplasms | 1 | 2010 | 375 | 0.270 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1624 | 0.270 |
Why?
|
Protein Kinase C | 2 | 2008 | 1202 | 0.260 |
Why?
|
Medical Oncology | 4 | 2019 | 2339 | 0.260 |
Why?
|
Protein Kinase Inhibitors | 7 | 2019 | 5696 | 0.260 |
Why?
|
Neoplasm Proteins | 4 | 2021 | 3596 | 0.250 |
Why?
|
Anthracyclines | 2 | 2023 | 284 | 0.250 |
Why?
|
Aged | 65 | 2025 | 171117 | 0.250 |
Why?
|
Tomography, X-Ray Computed | 14 | 2023 | 20659 | 0.250 |
Why?
|
Cancer Care Facilities | 1 | 2008 | 426 | 0.250 |
Why?
|
Central Nervous System Neoplasms | 4 | 2017 | 916 | 0.240 |
Why?
|
Sarcoma, Kaposi | 2 | 2019 | 375 | 0.240 |
Why?
|
Vascular Diseases | 1 | 2013 | 1159 | 0.240 |
Why?
|
Pyrazines | 3 | 2021 | 1204 | 0.240 |
Why?
|
Survival Rate | 15 | 2021 | 12795 | 0.230 |
Why?
|
Transplants | 1 | 2006 | 208 | 0.220 |
Why?
|
Recombinant Fusion Proteins | 1 | 2012 | 3737 | 0.220 |
Why?
|
Ifosfamide | 4 | 2014 | 233 | 0.210 |
Why?
|
Organ Transplantation | 2 | 2010 | 1174 | 0.210 |
Why?
|
Indoles | 2 | 2008 | 1839 | 0.210 |
Why?
|
Young Adult | 26 | 2024 | 59889 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2019 | 5337 | 0.200 |
Why?
|
Survival Analysis | 10 | 2020 | 10070 | 0.200 |
Why?
|
Immunologic Factors | 2 | 2009 | 1587 | 0.200 |
Why?
|
Neoplasms | 8 | 2024 | 22340 | 0.200 |
Why?
|
Lymphocytes | 1 | 2009 | 2599 | 0.190 |
Why?
|
Methotrexate | 5 | 2014 | 1722 | 0.180 |
Why?
|
Transplantation, Homologous | 7 | 2023 | 4860 | 0.180 |
Why?
|
Tumor Lysis Syndrome | 1 | 2021 | 37 | 0.180 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 891 | 0.180 |
Why?
|
Oxazines | 2 | 2015 | 358 | 0.180 |
Why?
|
Histiocytes | 1 | 2021 | 95 | 0.180 |
Why?
|
Cancer Vaccines | 2 | 2024 | 1044 | 0.180 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 8041 | 0.180 |
Why?
|
Carmustine | 3 | 2020 | 137 | 0.170 |
Why?
|
Adenine | 2 | 2024 | 994 | 0.170 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1471 | 0.170 |
Why?
|
Follow-Up Studies | 16 | 2024 | 39193 | 0.170 |
Why?
|
Radiotherapy | 5 | 2016 | 1494 | 0.170 |
Why?
|
Retreatment | 2 | 2019 | 598 | 0.170 |
Why?
|
Piperidines | 3 | 2024 | 1664 | 0.170 |
Why?
|
Neoplasm, Residual | 6 | 2023 | 1009 | 0.170 |
Why?
|
Music | 1 | 2023 | 249 | 0.170 |
Why?
|
Therapies, Investigational | 1 | 2021 | 110 | 0.170 |
Why?
|
Endemic Diseases | 1 | 2021 | 189 | 0.170 |
Why?
|
Adolescent | 26 | 2024 | 88835 | 0.170 |
Why?
|
Genes, myc | 1 | 2021 | 393 | 0.160 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 679 | 0.160 |
Why?
|
Drug Administration Schedule | 9 | 2021 | 4850 | 0.160 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 272 | 0.160 |
Why?
|
Neutropenia | 2 | 2023 | 893 | 0.160 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2024 | 712 | 0.150 |
Why?
|
Private Practice | 1 | 2019 | 154 | 0.150 |
Why?
|
Angiogenesis Inhibitors | 1 | 2008 | 2056 | 0.150 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 12976 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2016 | 190 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 751 | 0.150 |
Why?
|
Neoplasms, Second Primary | 5 | 2017 | 1050 | 0.150 |
Why?
|
Tumor Escape | 1 | 2021 | 371 | 0.150 |
Why?
|
Aged, 80 and over | 27 | 2025 | 59489 | 0.150 |
Why?
|
Heart | 2 | 2010 | 4414 | 0.150 |
Why?
|
Immunohistochemistry | 7 | 2014 | 11022 | 0.150 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2631 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3529 | 0.140 |
Why?
|
Remission Induction | 7 | 2021 | 2411 | 0.140 |
Why?
|
Time Factors | 8 | 2021 | 40065 | 0.140 |
Why?
|
Sulfonamides | 2 | 2021 | 1984 | 0.140 |
Why?
|
Myocardium | 1 | 2010 | 4760 | 0.140 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 416 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1560 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 851 | 0.140 |
Why?
|
Paclitaxel | 1 | 2024 | 1728 | 0.140 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2018 | 330 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
Pyridines | 3 | 2015 | 2888 | 0.130 |
Why?
|
Boronic Acids | 2 | 2010 | 916 | 0.130 |
Why?
|
Heart Diseases | 3 | 2023 | 2821 | 0.130 |
Why?
|
Herpesvirus 8, Human | 1 | 2018 | 254 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-rel | 2 | 2007 | 71 | 0.130 |
Why?
|
Databases, Factual | 1 | 2012 | 8067 | 0.130 |
Why?
|
Retrospective Studies | 26 | 2025 | 81514 | 0.130 |
Why?
|
Gene Rearrangement | 2 | 2018 | 1144 | 0.130 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2017 | 186 | 0.130 |
Why?
|
Pyrimidines | 4 | 2019 | 3047 | 0.130 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2017 | 227 | 0.130 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 3078 | 0.130 |
Why?
|
Age Factors | 5 | 2019 | 18380 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1377 | 0.130 |
Why?
|
Biological Products | 1 | 2025 | 942 | 0.120 |
Why?
|
Opportunistic Infections | 1 | 2018 | 376 | 0.120 |
Why?
|
Cohort Studies | 12 | 2016 | 41649 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 664 | 0.120 |
Why?
|
Immunophenotyping | 3 | 2016 | 1866 | 0.120 |
Why?
|
Exanthema | 1 | 2019 | 502 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2019 | 2942 | 0.120 |
Why?
|
Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 13 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 614 | 0.110 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2014 | 40 | 0.110 |
Why?
|
Sequence Deletion | 1 | 2018 | 1495 | 0.110 |
Why?
|
Europe | 1 | 2021 | 3423 | 0.110 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1385 | 0.110 |
Why?
|
Mentors | 1 | 2019 | 671 | 0.110 |
Why?
|
Prednisolone | 2 | 2018 | 324 | 0.110 |
Why?
|
Central Nervous System | 1 | 2021 | 1341 | 0.110 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 155 | 0.110 |
Why?
|
Immunotherapy | 4 | 2024 | 4752 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 3 | 2017 | 1404 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2878 | 0.100 |
Why?
|
Carotid Artery, Common | 1 | 2013 | 172 | 0.100 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2822 | 0.100 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9525 | 0.100 |
Why?
|
Herpes Zoster | 1 | 2015 | 252 | 0.100 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 111 | 0.100 |
Why?
|
Vaccination | 1 | 2024 | 3426 | 0.100 |
Why?
|
United States | 10 | 2021 | 72903 | 0.100 |
Why?
|
Viral Load | 3 | 2018 | 3386 | 0.090 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2017 | 1899 | 0.090 |
Why?
|
Radiation Pneumonitis | 1 | 2011 | 98 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 2017 | 786 | 0.090 |
Why?
|
HIV Infections | 5 | 2018 | 17533 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2016 | 633 | 0.090 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1315 | 0.090 |
Why?
|
Hydrocephalus | 1 | 2017 | 762 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1802 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1927 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4034 | 0.090 |
Why?
|
Antigens, CD | 1 | 2021 | 4025 | 0.090 |
Why?
|
Fever | 1 | 2017 | 1603 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1259 | 0.080 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1394 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2033 | 0.080 |
Why?
|
Specimen Handling | 1 | 2013 | 704 | 0.080 |
Why?
|
Hospice Care | 1 | 2015 | 678 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10261 | 0.080 |
Why?
|
Comorbidity | 5 | 2018 | 10563 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 533 | 0.080 |
Why?
|
Child | 10 | 2023 | 80564 | 0.070 |
Why?
|
Procarbazine | 2 | 2019 | 172 | 0.070 |
Why?
|
Preoperative Care | 1 | 2017 | 2267 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 6 | 2017 | 6499 | 0.070 |
Why?
|
Tachycardia | 1 | 2010 | 594 | 0.070 |
Why?
|
Leukemia | 1 | 2016 | 1522 | 0.070 |
Why?
|
Medical Errors | 1 | 2016 | 1260 | 0.070 |
Why?
|
Watchful Waiting | 1 | 2012 | 493 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3608 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4778 | 0.070 |
Why?
|
Treatment Failure | 2 | 2012 | 2652 | 0.070 |
Why?
|
Helicobacter pylori | 1 | 2011 | 380 | 0.070 |
Why?
|
Antigens, CD20 | 1 | 2008 | 198 | 0.070 |
Why?
|
TNF Receptor-Associated Factor 1 | 1 | 2007 | 48 | 0.070 |
Why?
|
Magnetic Resonance Angiography | 1 | 2013 | 1426 | 0.070 |
Why?
|
Bone Marrow Cells | 2 | 2013 | 2412 | 0.070 |
Why?
|
Databases as Topic | 1 | 2008 | 471 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2008 | 340 | 0.070 |
Why?
|
Troponin | 1 | 2010 | 533 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 950 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1857 | 0.060 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2008 | 248 | 0.060 |
Why?
|
Aorta | 1 | 2013 | 2028 | 0.060 |
Why?
|
Sirolimus | 2 | 2012 | 1545 | 0.060 |
Why?
|
Piperazines | 2 | 2016 | 2549 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2015 | 2423 | 0.060 |
Why?
|
Aniline Compounds | 1 | 2010 | 1075 | 0.060 |
Why?
|
Oligonucleotides | 1 | 2008 | 561 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7838 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4405 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2011 | 1259 | 0.060 |
Why?
|
Registries | 2 | 2013 | 8297 | 0.060 |
Why?
|
Mesna | 1 | 2004 | 62 | 0.060 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2011 | 888 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2017 | 3646 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2880 | 0.060 |
Why?
|
Administration, Oral | 3 | 2019 | 4015 | 0.060 |
Why?
|
Research Personnel | 1 | 2008 | 590 | 0.050 |
Why?
|
Sex Distribution | 1 | 2009 | 2263 | 0.050 |
Why?
|
Macrophages | 1 | 2018 | 5772 | 0.050 |
Why?
|
Lymphocyte Count | 2 | 2018 | 790 | 0.050 |
Why?
|
Thiazoles | 1 | 2011 | 1529 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2014 | 5881 | 0.050 |
Why?
|
Thiotepa | 2 | 2014 | 66 | 0.050 |
Why?
|
K562 Cells | 1 | 2024 | 649 | 0.050 |
Why?
|
Switzerland | 1 | 2023 | 322 | 0.050 |
Why?
|
Pregnancy | 1 | 2024 | 30260 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2008 | 3586 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2615 | 0.050 |
Why?
|
Busulfan | 2 | 2014 | 264 | 0.050 |
Why?
|
Leucovorin | 1 | 2004 | 641 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9443 | 0.050 |
Why?
|
Antigens, CD19 | 1 | 2025 | 443 | 0.050 |
Why?
|
Risk Factors | 9 | 2021 | 74840 | 0.050 |
Why?
|
Population Surveillance | 1 | 2012 | 2590 | 0.050 |
Why?
|
Hematologic Diseases | 2 | 2019 | 500 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 10383 | 0.050 |
Why?
|
DNA, Viral | 2 | 2018 | 2199 | 0.040 |
Why?
|
Quality Improvement | 1 | 2016 | 3853 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2024 | 616 | 0.040 |
Why?
|
Child, Preschool | 3 | 2018 | 42500 | 0.040 |
Why?
|
NAD | 1 | 2024 | 619 | 0.040 |
Why?
|
Protein Processing, Post-Translational | 1 | 2008 | 1957 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15398 | 0.040 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7425 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2024 | 748 | 0.040 |
Why?
|
Pneumonia | 1 | 2012 | 2157 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 3602 | 0.040 |
Why?
|
SEER Program | 2 | 2015 | 1446 | 0.040 |
Why?
|
Morpholines | 2 | 2015 | 577 | 0.040 |
Why?
|
Mediastinum | 2 | 2012 | 271 | 0.040 |
Why?
|
HIV-1 | 2 | 2017 | 6944 | 0.040 |
Why?
|
DNA | 1 | 2013 | 7202 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2453 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12437 | 0.040 |
Why?
|
Data Collection | 1 | 2008 | 3318 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2207 | 0.040 |
Why?
|
Mutation | 2 | 2021 | 30198 | 0.040 |
Why?
|
Aminopyridines | 2 | 2015 | 576 | 0.040 |
Why?
|
Biopsy | 1 | 2011 | 6763 | 0.040 |
Why?
|
Disease Progression | 5 | 2015 | 13632 | 0.040 |
Why?
|
Thalidomide | 2 | 2014 | 886 | 0.040 |
Why?
|
Pandemics | 3 | 2023 | 8703 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2023 | 811 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2007 | 2867 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 898 | 0.040 |
Why?
|
Podophyllotoxin | 1 | 2017 | 20 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4671 | 0.040 |
Why?
|
Prospective Studies | 6 | 2020 | 54802 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3513 | 0.030 |
Why?
|
Phosphorylation | 1 | 2008 | 8278 | 0.030 |
Why?
|
Methylprednisolone | 1 | 2018 | 386 | 0.030 |
Why?
|
Stress, Psychological | 2 | 2023 | 4533 | 0.030 |
Why?
|
NF-kappa B | 1 | 2005 | 2485 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 648 | 0.030 |
Why?
|
Axons | 1 | 2024 | 1682 | 0.030 |
Why?
|
Games, Experimental | 1 | 2016 | 32 | 0.030 |
Why?
|
Anemia | 2 | 2018 | 1511 | 0.030 |
Why?
|
Fatigue | 2 | 2014 | 1549 | 0.030 |
Why?
|
Curriculum | 2 | 2022 | 3782 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4209 | 0.030 |
Why?
|
Melphalan | 1 | 2017 | 425 | 0.030 |
Why?
|
Radiotherapy Dosage | 2 | 2012 | 2865 | 0.030 |
Why?
|
Apoptosis | 2 | 2008 | 9514 | 0.030 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 1995 | 282 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 350 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 354 | 0.030 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 102 | 0.030 |
Why?
|
Radioimmunotherapy | 1 | 2014 | 93 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14751 | 0.030 |
Why?
|
Herpesvirus 3, Human | 1 | 2015 | 159 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 360 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1417 | 0.030 |
Why?
|
Patient Selection | 2 | 2018 | 4255 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2008 | 20124 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10729 | 0.030 |
Why?
|
Boston | 2 | 2021 | 9338 | 0.030 |
Why?
|
Chemokines | 1 | 2017 | 956 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1672 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 911 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 240 | 0.030 |
Why?
|
Lung | 1 | 2011 | 10033 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 866 | 0.030 |
Why?
|
Phagocytosis | 1 | 2018 | 1520 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2017 | 751 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 368 | 0.020 |
Why?
|
Receptors, HIV | 1 | 2013 | 159 | 0.020 |
Why?
|
Hepatitis B Antibodies | 1 | 2013 | 156 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1776 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2014 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 315 | 0.020 |
Why?
|
Lymphopenia | 1 | 2014 | 297 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1731 | 0.020 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 294 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1837 | 0.020 |
Why?
|
Qualitative Research | 1 | 2023 | 3139 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2395 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 2729 | 0.020 |
Why?
|
Nausea | 1 | 2014 | 680 | 0.020 |
Why?
|
HIV | 1 | 2018 | 1585 | 0.020 |
Why?
|
Signal Transduction | 2 | 2019 | 23601 | 0.020 |
Why?
|
Gonads | 1 | 2011 | 109 | 0.020 |
Why?
|
Dosage Forms | 1 | 2010 | 55 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 249 | 0.020 |
Why?
|
Virus Activation | 1 | 2013 | 323 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2013 | 491 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 836 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5302 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3928 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12056 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3946 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13266 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2011 | 641 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2418 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 131 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2229 | 0.020 |
Why?
|
Virus Replication | 1 | 2017 | 2447 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5596 | 0.020 |
Why?
|
Hepatitis B virus | 1 | 2013 | 530 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2005 | 8611 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2012 | 352 | 0.020 |
Why?
|
RNA, Viral | 1 | 2017 | 2864 | 0.020 |
Why?
|
Educational Measurement | 1 | 2016 | 1260 | 0.020 |
Why?
|
Massachusetts | 2 | 2014 | 8875 | 0.020 |
Why?
|
Carboplatin | 1 | 2011 | 789 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4108 | 0.020 |
Why?
|
Teaching | 1 | 2016 | 1169 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2505 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8733 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1133 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2012 | 561 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2012 | 1752 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4642 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 544 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 233 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2017 | 2058 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1295 | 0.020 |
Why?
|
Hepatitis B | 1 | 2013 | 707 | 0.020 |
Why?
|
Leukocytes | 1 | 1995 | 2027 | 0.020 |
Why?
|
Incidence | 3 | 2015 | 21480 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2573 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8923 | 0.020 |
Why?
|
Medicare | 2 | 2015 | 6823 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 1941 | 0.020 |
Why?
|
Social Class | 1 | 2015 | 2007 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2017 | 5501 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3685 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2011 | 889 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1608 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3956 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1394 | 0.020 |
Why?
|
Heterozygote | 1 | 2013 | 2794 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1899 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 2968 | 0.020 |
Why?
|
Gene Deletion | 1 | 2013 | 2666 | 0.020 |
Why?
|
Transplantation Chimera | 1 | 2008 | 609 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 1472 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4520 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3111 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1660 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3106 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2844 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1326 | 0.010 |
Why?
|
Thrombosis | 1 | 2017 | 2949 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36532 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3344 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9649 | 0.010 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1787 | 0.010 |
Why?
|
Palliative Care | 1 | 2018 | 3645 | 0.010 |
Why?
|
Medical Records | 1 | 2008 | 1409 | 0.010 |
Why?
|
Diarrhea | 1 | 2009 | 1316 | 0.010 |
Why?
|
Hepatitis C | 1 | 2013 | 1597 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3413 | 0.010 |
Why?
|
Neutrophils | 1 | 1995 | 3776 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2018 | 4559 | 0.010 |
Why?
|
Lung Transplantation | 1 | 2011 | 1311 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10603 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6209 | 0.010 |
Why?
|
Blood Platelets | 1 | 2010 | 2464 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6493 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9601 | 0.010 |
Why?
|
Heart Failure | 1 | 2023 | 11840 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 13039 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16721 | 0.010 |
Why?
|
Karyotyping | 1 | 1999 | 1178 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15747 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9347 | 0.010 |
Why?
|
Inflammation | 1 | 1995 | 10850 | 0.010 |
Why?
|
Risk Assessment | 2 | 2011 | 24282 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15880 | 0.010 |
Why?
|
Algorithms | 1 | 2015 | 14071 | 0.010 |
Why?
|
Peritonitis | 1 | 1995 | 369 | 0.010 |
Why?
|
P-Selectin | 1 | 1995 | 597 | 0.010 |
Why?
|
Mice | 2 | 2016 | 81819 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14652 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1995 | 1602 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 15842 | 0.010 |
Why?
|
Hypertension | 1 | 2009 | 8626 | 0.010 |
Why?
|
Cell Adhesion | 1 | 1995 | 3089 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17075 | 0.000 |
Why?
|
Animals | 2 | 2016 | 168764 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 18071 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1995 | 4427 | 0.000 |
Why?
|
Mice, Knockout | 1 | 1995 | 14448 | 0.000 |
Why?
|